<DOC>
	<DOC>NCT00259935</DOC>
	<brief_summary>The purpose of this study is to determine the bioequivalence of the new oral capsule formulation to the currently used oral capsule formulation of topotecan.</brief_summary>
	<brief_title>A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Subjects with advanced solid tumors. At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery. Subjects must be free of posttreatment side effects. Women who are pregnant or lactating Subjects with uncontrolled emesis, regardless of etiology, active infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Any Solid Tumor</keyword>
</DOC>